| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11018161 | Urologic Oncology: Seminars and Original Investigations | 2018 | 10 Pages |
Abstract
Past studies on NAR show inconclusive results and NAR is rarely administered. Instead, CB-NAC is advised in eligible patients with cT2-4aN0M0 MIBC prior to RC. In the near future, predictive biomarkers will be the key to tailor the use of CB-NAC and reduce harm to nonresponders.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Tom J.N. M.D., Charlotte S. M.D., Michiel S. M.D., Ph.D., Bernd J. M.D., Ph.D., Wassim M.D., C.M., F.R.C.S.C., Roland M.D., Ashish M. M.D., M.B.B.S., F.A.C.S., Petros M.D., Ph.D., Anne E. M.A., D.M., D.Sc., Peter C. M.D., F.R.C.S.C., F.A.C.S.,